MX2017014301A - Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar. - Google Patents

Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar.

Info

Publication number
MX2017014301A
MX2017014301A MX2017014301A MX2017014301A MX2017014301A MX 2017014301 A MX2017014301 A MX 2017014301A MX 2017014301 A MX2017014301 A MX 2017014301A MX 2017014301 A MX2017014301 A MX 2017014301A MX 2017014301 A MX2017014301 A MX 2017014301A
Authority
MX
Mexico
Prior art keywords
pulmonary hypertension
prevention
treatment
methods
compositions
Prior art date
Application number
MX2017014301A
Other languages
English (en)
Inventor
Gu Leo
S Banait Narinder
Original Assignee
Vivus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivus Inc filed Critical Vivus Inc
Publication of MX2017014301A publication Critical patent/MX2017014301A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona composiciones y métodos para el tratamiento o prevención de hipertensión pulmonar que comprenden administrar una ascomicina, o una sal, solvato, análogo, o profármaco farmacéuticamente aceptable de la misma al paciente con hipertensión pulmonar.
MX2017014301A 2015-05-08 2016-05-04 Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar. MX2017014301A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562159162P 2015-05-08 2015-05-08
PCT/US2016/030737 WO2016182813A1 (en) 2015-05-08 2016-05-04 Compositions and methods for the treatment or prevention of pulmonary hypertension

Publications (1)

Publication Number Publication Date
MX2017014301A true MX2017014301A (es) 2018-03-23

Family

ID=57249333

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014301A MX2017014301A (es) 2015-05-08 2016-05-04 Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar.

Country Status (10)

Country Link
US (3) US20180125828A1 (es)
EP (1) EP3294294A4 (es)
KR (1) KR20180002822A (es)
CN (1) CN107708695A (es)
AU (1) AU2016262391A1 (es)
BR (1) BR112017023817A2 (es)
CA (1) CA2985080A1 (es)
MX (1) MX2017014301A (es)
RU (1) RU2017142589A (es)
WO (1) WO2016182813A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11417416B2 (en) * 2018-06-14 2022-08-16 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
CN112569357B (zh) * 2019-09-30 2023-03-28 深圳奥萨制药有限公司 双重内皮素受体拮抗剂与利尿剂的组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE268185T1 (de) * 2000-07-14 2004-06-15 Healthecon Ag Grüntee-extrakt zur behandlung von cyclosporin oder ascomycin induzierten nieren- funktionsstörungen
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
FI3821891T3 (fi) * 2011-05-02 2023-08-24 Univ Leland Stanford Junior FK506:n käyttö pulmonaarisen valtimohypertension hoidossa
US20130225595A1 (en) * 2012-02-29 2013-08-29 Gilead Sciences, Inc. Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis

Also Published As

Publication number Publication date
EP3294294A4 (en) 2019-01-02
US20200054613A1 (en) 2020-02-20
RU2017142589A3 (es) 2019-09-26
RU2017142589A (ru) 2019-06-10
AU2016262391A1 (en) 2017-11-23
BR112017023817A2 (pt) 2018-07-31
US20180125828A1 (en) 2018-05-10
CN107708695A (zh) 2018-02-16
US20210338642A1 (en) 2021-11-04
EP3294294A1 (en) 2018-03-21
CA2985080A1 (en) 2016-11-17
KR20180002822A (ko) 2018-01-08
WO2016182813A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
PH12016501750A1 (en) Human plasma kallikrein inhibitors
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
PH12016502256A1 (en) Medical use
SG10201811384TA (en) Mnk inhibitors and methods related thereto
MY190835A (en) Bicyclic heterrocyclic derivatives as bromodomain inhibitors
NZ735044A (en) Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MX2017004440A (es) Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar.
MX2017001103A (es) Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
MX2022013450A (es) Formulaciones farmaceuticas.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
MX2017014301A (es) Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar.
TR201714882A2 (tr) Luli̇konazolün topi̇kal farmasöti̇k kompozi̇syonlari
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2017002627A (es) Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak.
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
IN2014MU00859A (es)
MX2019008847A (es) Profarmacos de cisteamina.
MX2018012587A (es) (+)-azasetron para uso en el tratamiento de trastornos del oido.
MX2017002747A (es) Derivados de polieteres macrociclicos de n-aril-triciclopirimidin- 2-amino como inhibidores de ftl3 y jak.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
IN2014DE00822A (es)